Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $7.0252W HIGH $12.41
Volume
604.73 K
Value Traded
2.34 M
Short % Float
3.47%
-2.9%Week
-19.1%1 Month
-23.86%3 Month
-29.34%6 Month
+5.64%5 Year
+22.32%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
1.01 B
EPS (TTM)
-1.97
P/E Ratio
-
Ent. Value
1.05 B
Total Shares
136.69 M
Float Shares
127.72 M
Insiders
14.65%
Institutions
65.04%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
IMTX Catalyst Timeline
Dated clinical, regulatory and corporate events for Immatics N.V.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Immatics N.V.
244Total events
23Upcoming
78Tier-1 (high impact)
2018 to 2027Coverage
Upcoming catalysts 2
Event history 50
●Trial InitiationIMA402Trial
Phase 1b combination cohort initiated in sqNSCLC
squamous non-small cell lung cancersource ↗
▲First Patient DosedmRNA-4200Trial
First patient dosed in Moderna-sponsored trial of mRNA-4200
cancersource ↗
◆Oral PresentationIMA203Presentation
Patient-level clinical response dynamics in advanced melanoma with anzu-cel
advanced cutaneous and uveal melanomasource ↗
▲Full ResultsIMA203Clinical Data
Extended Phase 1b data for anzu-cel released at ASCO 2026
metastatic melanomasource ↗
◆Oral PresentationIMA203Presentation
Oral presentation: Patient-level clinical response dynamics in advanced melanoma with anzu-cel
advanced melanomasource ↗
▲Oral PresentationIMA203Presentation
Updated Phase 1b data presented at ASCO 2026
metastatic melanomasource ↗
▲Oral PresentationIMA203CD8Presentation
Updated Phase 1 data for IMA203CD8 presented at ASCO 2026
gynecologic cancerssource ↗
◆Oral PresentationIMA203CD8Presentation
Phase 1 study results with PRAME-directed TCR T-cell therapies in synovial sarcoma
synovial sarcomasource ↗
◆Oral PresentationIMA401Presentation
First-in-human results with IMA401, a MAGEA4/8 targeted TCER
recurrent or refractory solid tumorssource ↗
▲PublicationIMA401Presentation
Simultaneous publication of IMA401 Phase 1 results in Nature Medicine
solid tumorssource ↗
◆Oral PresentationIMA203CD8Presentation
Oral presentation: Phase 1a study results for IMA203CD8 in ovarian cancer
ovarian cancersource ↗
▲Trial InitiationIMA401Trial
Initiation of enrollment in IMA401/IMA402 combination cohort in sqNSCLC
squamous cell non-small cell lung cancersource ↗
◆Late-BreakerPresentation
Late-breaking poster presentation at AACR 2026 on pediatric patient case
PRAME-positive advanced nephroblastomasource ↗
◆Oral PresentationPresentation
Poster presentation at AACR 2026 by Dr. Christian M. Seitz
PRAME-positive advanced nephroblastomasource ↗
▲Full ResultsIMA203CD8Clinical Data
Deep and durable remission in pediatric patient with advanced metastatic nephroblastoma at 6 months follow-up
PRAME-positive solid tumors (pediatric nephroblastoma)source ↗
◆Full ResultsIMA203CD8Clinical Data
Updated data including durability follow-up at RP2D planned for presentation
solid tumors (ovarian and uterine cancer)source ↗
◆Interim AnalysisIMA203Trial
Pre-specified interim data analysis for PFS events
unresectable or metastatic cutaneous melanomasource ↗
▲Milestone PaymentCorporate
Moderna collaboration expansion triggered $5 million milestone payment to Immatics in January 2026
▲Oral PresentationIMA203CD8Presentation
Updated Phase 1a dose escalation data for IMA203CD8 presented at ESMO-IO 2025
PRAME-positive solid tumorssource ↗
▼Equity OfferingCorporate
Announced $125 million underwritten offering of 12,500,000 ordinary shares at $10.00 per share
●Oral PresentationPresentation
Conference call and webcast to present TCR Bispecifics dataset and next development steps
▲Topline ReadoutIMA402Clinical Data
Updated Phase 1a dose escalation data for IMA402 PRAME Bispecific
Advanced metastatic solid tumorssource ↗
▲Topline ReadoutIMA401Clinical Data
Updated Phase 1a dose escalation data for IMA401 MAGEA4/8 Bispecific
Heavily pre-treated patients with broad range of tumor typessource ↗
▲Primary Endpoint MetIMA402Clinical Data
Clinical proof-of-concept achieved for IMA402
Advanced metastatic solid tumorssource ↗
▲Primary Endpoint MetIMA401Clinical Data
Clinical proof-of-concept achieved for IMA401
Recurrent and/or refractory solid tumorssource ↗
●Enrollment MilestoneIMA203CD8Trial
78 patients enrolled as of data cutoff October 27, 2025
PRAME-positive solid tumorssource ↗
▲Oral PresentationIMA203Presentation
Updated data from 16 patients with metastatic uveal melanoma treated with anzu-cel presented at ESMO 2025 Presidential Symposium
metastatic uveal melanomasource ↗
▲Trial InitiationIMA203Trial
Initiated Phase 2 cohort with approximately 30 uveal melanoma patients
metastatic uveal melanomasource ↗
◆Oral PresentationIMA203Presentation
Ph1a dose escalation data at ESMO-IO
ovarian cancer, melanoma, synovial sarcomasource ↗
▲Enrollment CompleteIMA402Trial
Phase 1a dose escalation completed for IMA402
Advanced metastatic solid tumorssource ↗
▲Enrollment CompleteIMA401Trial
Phase 1a dose escalation completed for IMA401
Heavily pre-treated patients with broad range of tumor typessource ↗
▲Enrollment MilestoneIMA203Trial
16 patients with metastatic uveal melanoma enrolled and dosed at RP2D as of September 24, 2025
metastatic uveal melanomasource ↗
▲First Patient Dosedanzutresgene autoleucelTrial
First patient dosed in Phase 1 anzu-cel and mRNA-4203 combination trial in 3Q 2025
solid tumorssource ↗
●Poster PresentationIMA203Presentation
Trial in Progress poster for SUPRAME Phase 3 trial at ASCO 2025
unresectable or metastatic cutaneous melanomasource ↗
Past FDA Catalysts and PDUFA Decisions
How IMTX actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-05-30 | IMA203CD8 (GEN2) | Phase 1a data readout | Phase 1a |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
C56 / 100
Pipeline Score
$1.0B
Pipeline Value
Fair Value
Valuation Signal
6
Drugs Scored
1.0x
rNPV / MCap
Top 10%
Micro Cap(rank 67 of 658)
Percentile Rank
Immatics N.V. carries a moderate pipeline score (56/100), with $3.6B risk-adjusted pipeline value, led by IMA203 in Refractory Cancer (Phase 1), across $141B in total addressable markets.
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| IMA203 Monoclonal antibodyNCT06743126 | Melanoma, Cutaneous Malignant | Phase 3 | RECRUITING | 360 | Oct 1, 2031 |
Clinical Trial Results
Readouts, endpoints and source filings for every IMTX program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| anzu-cel RMATOrphan | advanced melanoma | Phase 3 | 2026-08-18 | 56% cORR; 14.6 months mDOR; 6.1 months mPFS; 16.2 months mOS; 2-year OS rate of 46%; 63% ORR; 50% cORRRead More | Immatics Announces Second Quarter 2026 Financial Results and Business UpdateRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| PERCEPTIVE ADVISORS LLCDirector | Buy | 863,060 11,246,516 held | $8.69 | 08/26/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in IMTX
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| RTW INVESTMENTS, LP | 1.1 % (-15.4 %) | 131.14 M | 12.95 M | 0.6% ( 76.84 K) |
IMTX Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How IMTX ranks across every disease it competes in
Competitive Position is a premium feature
See how IMTX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialIMTX News
IMTX▲ +6.3%on this news
Immatics Announces $150 Million Underwritten Offering
Immatics N.V. has announced an underwritten offering of approximately $150 million, selling nearly 13 million ordinary shares at $8.69 each. The offering is expected to close on August 26, 2026, and includes pre-funded warrants. Jefferies, Leerink Partners, and Cantor are managing the offering, which aims to bolster the company's clinical programs targeting PRAME.
Read more →IMTXImmatics Announces Second Quarter 2026 Financial Results and Business Update
Immatics N.V. reported its Q2 2026 financial results, highlighting progress in the SUPRAME Phase 3 trial for anzu-cel, which is on track for completion by year-end. The company plans a streamlined final analysis for the primary endpoint and aims to strengthen the secondary endpoint's statistical power. Updated data from ongoing trials show promising results in various cancers, with a strong cash position supporting future operations.
Read more →IMTXImmatics Announces Upcoming Presentations Across Its PRAME Franchise at ESMO Congress 2026
Immatics N.V. announced three presentations at the ESMO Congress 2026, showcasing data from its PRAME-targeted therapies. The presentations will cover Phase 1b data for its lead cell therapy, as well as Phase 1 data for another cell therapy and a bispecific T-cell engager. These findings underline the company's commitment to advancing cancer treatment through precision targeting.
Read more →IMTXMINUTES OF THE ANNUAL GENERAL MEETING OF SHAREHOLDERS OF IMMATICS N.V. JUNE 18, 2026 Edward Sturchio, General Counsel of Immatics N.V. (the Company ), opened the annual general meeting of the Company (the Meeting ) and d
The annual general meeting of shareholders of Immatics N.V. took place where General Counsel Edward Sturchio opened the meeting. The meeting was conducted in line with Dutch law and the company’s articles of association, with approximately 64.07% of the issued share capital represented. There were no comments or questions from shareholders during the meeting, allowing the agenda items to proceed directly to voting. All agenda items passed with the necessary majority votes.
Read more →IMTX▼ -9.9%on this news
CONVENING NOTICE OF the ANNUAL GENERAL MEETING OF IMMATICS N.V. This is the convening notice for the annual general meeting of Immatics N.V., a public company under Dutch law, registered with the Dutch trade register und
Immatics N.V. has issued a convening notice for its Annual General Meeting (AGM) scheduled for June 18, 2026, in Amsterdam. The notice details the required procedures for shareholders to attend or vote at the meeting, including deadlines for Attendance Notices and proxy submissions. Shareholders must meet specific criteria based on ownership and record dates to participate. Additional information related to the AGM is available on the company's official website.
Read more →IMTXImmatics Presents Clinical Activity and Response Dynamics of Anzu-cel PRAME Cell Therapy at 2026 ASCO Annual Meeting
Immatics presented promising data on anzu-cel, a PRAME cell therapy, at the 2026 ASCO Annual Meeting. The therapy showed a 56% confirmed overall response rate and durable anti-tumor activity in metastatic melanoma patients. With manageable tolerability, anzu-cel is advancing towards a Phase 3 trial and potential BLA submission in early 2027.
Read more →IMTXImmatics Presents Data on IMA401 MAGEA4/8 Bispecific at 2026 ASCO Annual Meeting with Simultaneous Publication in Nature Medicine Supporting Development of IMA401/IMA402 Combination in Lung Cancer
Immatics presented promising data on IMA401, a TCR bispecific targeting MAGEA4/8, at the 2026 ASCO Annual Meeting. The treatment showed deep and durable responses in various cancers, including melanoma and head and neck cancer, with a notable initial signal in lung cancer. The data support the development of a combination therapy with IMA402, which is currently enrolling patients for a Phase 1 trial.
Read more →IMTXClinical Activity of IMA203CD8 PRAME Cell Therapy in Hard-to-Treat Gynecologic Cancers at 2026 ASCO Annual Meeting
Immatics N.V. has presented updated Phase 1 data for its IMA203CD8 PRAME TCR T-cell therapy, which shows notable clinical activity in hard-to-treat gynecologic cancers and synovial sarcoma at the 2026 ASCO Annual Meeting. The therapy demonstrated anti-tumor activity with a one-time infusion showing promise in patients with limited treatment options. The company plans to broaden the evaluation of IMA203CD8 to additional PRAME-positive solid tumors based on the encouraging results so far.
Read more →IMTXImmatics Presents Clinical Activity of IMA203CD8 PRAME Cell Therapy in Hard-to-Treat Gynecologic Cancers at 2026 ASCO Annual Meeting
Immatics N.V. presented promising Phase 1 data for its IMA203CD8 PRAME cell therapy at the 2026 ASCO Annual Meeting. The therapy showed significant anti-tumor activity in hard-to-treat gynecologic cancers, achieving a 63% objective response rate in ovarian cancer. Additionally, it demonstrated durable responses in synovial sarcoma, with manageable tolerability. The company plans to expand its clinical evaluation into other PRAME-positive solid tumors.
Read more →IMTXPRELIMINARY NOTE The unaudited interim condensed Consolidated Financial Statements for the three-month period ended
Immatics N.V. reported its unaudited interim condensed consolidated financial statements for the three-month period ended March 31, 2026. The financial results indicate a significant net loss of €57,814,000, which is a substantial increase from the previous year's loss of €39,855,000. Research and development expenses also saw a notable rise, reflecting ongoing investments in product development. Additionally, the total comprehensive loss for the quarter was recorded at €55,939,000, compared to €42,566,000 in Q1 2025.
Read more →IMTXImmatics Announces First Quarter 2026 Financial Results and Business Update
Immatics N.V. reported its financial results for Q1 2026, highlighting significant progress in its clinical pipeline, particularly with the PRAME cell therapy, anzu-cel. The company anticipates multiple clinical data readouts in 2026 and is preparing for its first commercial launch in 2027. Despite a net loss of $66.5 million, Immatics maintains a strong cash position of $521.5 million.
Read more →IMTXImmatics Announces Four Upcoming Oral Presentations Across Its Clinical Cell Therapy and Bispecific at 2026 ASCO Annual Meeting
Immatics N.V. has announced that all submitted abstracts will be presented at the 2026 ASCO Annual Meeting, focusing on its clinical cell therapy and bispecific programs. The presentations will feature data on various therapies targeting PRAME, which is expressed in over 50 types of cancer. This showcases the advancement of Immatics' PRAME franchise and emphasizes its commitment to developing innovative immunotherapies. The meeting is set to take place in Chicago from May 29 to June 2, 2026.
Read more →IMTXImmatics Announces Four Upcoming Oral Presentations Across Its Clinical Cell Therapy and Bispecific Portfolio at 2026 ASCO Annual Meeting
Immatics N.V. announced that all its submitted abstracts have been selected for oral presentations at the 2026 ASCO Annual Meeting. The presentations will cover clinical data on its lead PRAME cell therapy, an updated dose-escalation study for a second-generation candidate, and results from bispecific therapies. These findings highlight the company's commitment to advancing immunotherapies for solid tumors.
Read more →IMTXCell Therapy Using Immatics' TCR Induces Deep and Durable Remission in Pediatric Patient
Immatics N.V. reported a significant case where a 17-year-old patient with advanced nephroblastoma experienced deep remission after receiving the company's PRAME-directed T-cell receptor therapy. The treatment was a last-ditch effort after other options had failed. With thorough monitoring, positive results included marked tumor regression and the absence of tumor-derived DNA in subsequent tests. This case highlights the potential of PRAME-targeted cell therapies for pediatric cancers.
Read more →IMTXPRAME-directed Cell Therapy Using Immatics’ TCR Induces Deep and Durable Remission in Pediatric Patient with Advanced Metastatic Nephroblastoma
Immatics announced a successful case of PRAME-directed TCR T-cell therapy in a 17-year-old with advanced nephroblastoma. The patient, having exhausted all treatment options, achieved deep remission with ongoing positive results at six months. This case underscores the potential of PRAME-targeted therapies in pediatric oncology, with plans for further clinical evaluations.
Read more →IMTXImmatics Announces Full Year 2025 Financial Results and Business Update
Immatics reported its full-year 2025 financial results, highlighting progress in its PRAME cell therapy programs, particularly anzu-cel, which is in a Phase 3 trial for advanced melanoma. The company expects to submit a BLA in the first half of 2027, with commercial launch anticipated in the second half of 2027. Despite a net loss of $230.8 million, Immatics maintains a strong cash position to support ongoing development.
Read more →IMTXImmatics Announces Full Year 2025 Financial Results and Business Update Anzu-cel (anzutresgene autoleucel, IMA203) PRAME Cell Therapy: Global, randomized, controlled Phase 3 trial, SUPRAME, in previously tr
Immatics N.V. has reported its financial results and business updates for the year ending December 31, 2025. The company is advancing its lead PRAME cell therapy, anzu-cel (IMA203), towards approval while also exploring second-generation therapies and bispecifics. Despite a significant net loss and decline in total revenue compared to the previous year, Immatics has a solid cash reserve of $551.4 million. The company is focused on expanding the reach of its PRAME therapies to better address advanced cancers.
Read more →IMTXImmatics. Not for further reproduction or distribution. Immatics. Not for further reproduction or distribution. Immatics Corporate Presentation
Immatics N.V. presented information regarding its corporate strategy and clinical pipeline, emphasizing its focus on the PRAME protein as a target for cancer therapies. The presentation highlights the company’s leadership in precision targeting and describes the various clinical product candidates under development. It also outlines the risks associated with forward-looking statements and the inherent uncertainties in predicting future performance. Immatics aims to advance its strategy through partnerships and clinical trials across multiple cancer types.
Read more →IMTXImmatics Presents IMA203CD8 PRAME Cell Therapy Data from Ongoing Dose Escalation and Shows Promising Initial Anti-tumor Activity in PRAME-Positive Tumors at ESMO-IO 2025 Congress
Immatics presented updated Phase 1a data for its IMA203CD8 PRAME cell therapy at the ESMO-IO 2025 Congress. The therapy showed promising initial anti-tumor activity in heavily pre-treated patients with solid tumors expressing PRAME. Notably, the treatment demonstrated manageable tolerability and deep objective responses, including complete responses in some patients. The company aims to continue dose escalation and further evaluate the therapy's potential in various cancers.
Read more →IMTXIMA203CD8 PRAME Cell Therapy Data from Ongoing Dose Escalation and Shows Promising Initial Anti-tumor Activity
Immatics N.V. presented updated Phase 1a dose escalation data for its second-generation PRAME cell therapy, IMA203CD8, at the ESMO-IO 2025 Congress. The therapy demonstrated promising initial anti-tumor activity among heavily pre-treated patients with PRAME-positive tumors, including ovarian carcinoma. With manageable tolerability and durable responses observed, IMA203CD8 showcases potential benefits for patients who have limited treatment options. The ongoing trial aims to determine the recommended Phase 2 dose, leveraging the therapy's indication across solid tumors beyond melanoma.
Read more →About Immatics N.V.
BIOPHARMAWATCH ELITE PLUS
Trade the next IMTX catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime